Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion O...
FDA Drug Recall #D-0316-2021 — Class I — February 18, 2021
Recall Summary
| Recall Number | D-0316-2021 |
| Classification | Class I — Serious risk |
| Date Initiated | February 18, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Zydus Pharmaceuticals (USA) Inc |
| Location | Pennington, NJ |
| Product Type | Drugs |
| Quantity | 1,638 packs |
Product Description
Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 10mL Single-Dose Vials per pack NDC 68382-048-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.
Reason for Recall
Crystallization: customer complaints for crystallization in finished product.
Distribution Pattern
USA Nationwide
Lot / Code Information
Lot#: L000126, L000127, Exp 12/31/2021
Other Recalls from Zydus Pharmaceuticals (USA) Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0400-2026 | Class II | Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... | Mar 9, 2026 |
| D-0295-2026 | Class II | Icosapent Ethyl capsules, 1 gram, 120-count bot... | Dec 30, 2025 |
| D-0247-2026 | Class III | traZODONE Hydrochloride Tablets, USP, 100mg, 1,... | Dec 19, 2025 |
| D-0159-2026 | Class II | Bromocriptine Mesylate Capsules, USP, 5 mg, 30 ... | Oct 23, 2025 |
| D-0152-2026 | Class II | clomiPRAMINE Hydrochloride, Capsules, USP, 25 m... | Oct 22, 2025 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.